DDIT3 and diffuse large B-cell lymphoma: The combination of atezolizumab with frontline R-CHOP was tested on DLBCL patients [89,90] as a combination of pembrolizumab with R-CHOP in patients with either DLBCL or grade 3b FL (Table 3) [91].